The Future of Antipsychotic Medication - Conversations with Dr Stephen Stahl

 

This interview is the sixth as part of a series of brief interviews where Dr. Sanil Rege talks to Dr. Stephen Stahl about key issues that face psychiatry and our patients. Dr. Stahl, MD, is a practicing Psychiatrist in Carlsbad, USA, and author of the best-selling textbook, Essential Psychopharmacology. Some of the Newer Pathways for Antipsychotic Development Pure 5HT2A receptor antagonism e.g. Pimavanserin in the psychosis of Parkinson’s disease Glutamate - based therapies raised hope but were not successful in long term trials, this remains back to the drawing board. Cognitive enhancers – Boosting acetylcholine at nicotinic receptors e.g. Encenicline - α7 nicotinic receptor partial agonist NMDA hypofunction hypothesis of Schizophrenia. Full article: https://psychscenehub.com/video/future-antipsychotic-medication-conversations-dr-stephen-stahl/